Treatment Adherence Strategies in mCSPC

Panelists discuss how adherence to oral androgen receptor pathway inhibitor (ARPI) therapy plays a critical role in achieving optimal outcomes for patients with metastatic castration-sensitive prostate cancer (mCSPC). Because ARPIs are self-administered at home, maintaining consistency can be challenging, especially for patients managing fatigue, complex medication schedules, or multiple comorbidities. The panel emphasizes that early, ongoing assessment of adherence—through both patient communication and objective monitoring—helps identify barriers before they compromise treatment effectiveness.

Panelists discuss how practical strategies can improve long-term adherence and quality of life. These include scheduling regular follow-ups, using electronic reminders or pill organizers, involving pharmacists in medication reconciliation, and engaging caregivers when appropriate. Education at treatment initiation is essential: patients need to understand why daily dosing matters, what adverse effects to expect, and how to report problems promptly. By setting clear expectations and maintaining open communication, clinicians help patients feel supported rather than overwhelmed by therapy demands.

Panelists discuss how adherence directly impacts real-world outcomes, with studies showing that consistent ARPI use correlates with longer disease control and improved survival. Addressing nonadherence early prevents unnecessary therapy changes and fosters patient empowerment. Ultimately, adherence is not only about taking medication correctly—it’s about building trust, providing education, and ensuring that patients have the tools and support to succeed in treatment.